Potential metabolite of PGE2
Related Products
Isomer(s)
26702tetranor-Prostaglandin E1
Parent Compound(s)
14010Prostaglandin E2
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

13,14-dihydro-15-keto-tetranor Prostaglandin E2

Item No. 13101

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
[1R-(1α,2β,3α)]-3-hydroxy-5-oxo-2-(3-oxooctyl)-cyclopentanepropanoic acid
CAS Number
20675-85-8
Synonyms
  • 13,14-dihydro-15-keto-tetranor PGE2
Molecular Formula
C16H26O5
Formula Weight
298.4
Purity
≥95%
Formulation (Request formulation change)
A 100 µg/ml solution in ethanol
Solubility(Learn about Variance in Solubility)
DMF: 50 mg/mlDMSO: 50 mg/mlEthanol: 50 mg/mlPBS (pH 7.2): 1 mg/ml
SMILES
CCCCCC(CC[C@H]([C@H]1CCC(O)=O)[C@H](O)CC1=O)=O
InChi Code
InChI=1S/C16H26O5/c1-2-3-4-5-11(17)6-7-12-13(8-9-16(20)21)15(19)10-14(12)18/h12-14,18H,2-10H2,1H3,(H,20,21)/t12-,13-,14-/m1/s1
InChi Key
FGACPXKRXBKDQL-MGPQQGTHSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    10 µg

    $108

    Add

    25 µg

    $256

    Add

    50 µg

    $481

    Add
    Lipid Resource Center
    Discover Products & Resources for Lipid Research
    • High-purity lipid standards
    • Lipid roles in biology
    • Lipids in health & disease
    • Lipids for pharmaceutical development
    • Protocols, advice, & resources
    EXPLORE NOW
    Product Description

    A common metabolic pathway for several prostaglandins (PG), including PGE2, involves the reduction of the double bond between C-13 and C-14 and oxidation of the hydroxyl group at C-15, producing 13,14-dihydro-15-keto PGs. The removal of four carbons at the α-terminus and oxidation of the terminal ω-carbon produces the abundant urinary metabolites, including tetranor PGEM.1 13,14-dihydro-15-keto-tetranor PGE2 is a potential metabolite of PGE2. It would be produced from the known metabolite 13,14-dihydro-15-keto PGE2 (Item No. 14650), which is known to have a short plasma half-life.2,3,4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Hamberg, M. Inhibition of prostaglandin synthesis in man. Biochem. Biophys. Res. Commun. 49(3), 720-726 (1972).

    2. Bothwell, W., Verburg, M., Wynalda, M., et al. A radioimmunoassay for the unstable pulmonary metabolites of prostaglandin E1 and E2: An indirect index of their in vivo disposition and pharmacokinetics. J. Pharmacol. Exp. Ther. 220(2), 229-235 (1982).

    3. Fitzpatrick, F.A., Aguirre, R., Pike, J.E., et al. The stability of 13,14-dihydro-15 keto-PGE2. Prostaglandins 19(6), 917-931 (1980).

    4. Granström, E., Hamberg, M., Hansson, G., et al. Chemical instability of 15-keto-13,14-dihydro-PGE2: The reason for low assay reliability. Prostaglandins 19(6), 933-945 (1980).